{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
Restrict the search for
m triheptanoin
to a specific field?
Status:
Other
Class (Stereo):
CHEMICAL (ACHIRAL)
Targets:
Conditions:
AG-3-5 (also known as icilin) was first identified as a super-cooling agent in the early 1980s and bears little resemblance to menthol structurally. Icilin is able to activate both TRPM8 and TRPA1 channel activity. Icilin alleviates pain sensation in animal models.
Status:
Other
Class (Stereo):
CHEMICAL (ABSOLUTE)
Conditions:
Elaiophylin (also known as Azalomycin-B) is a natural compound, a macrolide antibiotic that was first isolated from a culture of Streptomyces melanosporus. Elaiophylin is a novel and potent inhibitor of late-stage autophagy with outstanding antitumor activity in human ovarian cancer cells. In addition was shown, that elaiophylin could be a promising therapeutic strategy for overcoming incurable multiple myeloma (MM), even when TP53 mutations are present. It is known, that autophagy inhibition is a promising approach and is being investigated as a new target strategy for ovarian cancer treatment. Autophagy, a lysosome-dependent pathway, is a complex catabolic process that involves the degradation of dysfunctional or useless cytoplasmic constituents. Thus, elaiophylin, a novel autophagy inhibitor with unique chemical structure, provides the potential for structure-based development of autophagy inhibitors for new cancer therapies. Also, elaiophylin is an inhibitor of a testosterone 5 alpha-reductase.
Status:
Other
Class (Stereo):
CHEMICAL (ACHIRAL)
Conditions:
3-Hydroxymethyl-beta-carboline (3-HMC) is a benzodiazepine receptor antagonist both in vitro and in vivo. It antagonizes both the anticonvulsant and “anxiolytic” actions of diazepam. 3-HMC decreases sleep and reverses the hypnotic actions of flurazepam. 3-HMC is an active antagonist of the cerebrovascular and cerebral metabolic depression produced by flurazepam and can stimulate cerebral blood flow and cerebral O2 consumption at high doses when given alone. 3-HMC has the ability to specifically antagonize fentanyl anesthesia.
